Strategy

Apr 01, 2005
Pharmaceutical Executive
Every quarter, pharmaceutical manufacturers confront a dizzying array of price reporting obligations. Participation in the Medicare, Medicaid, Veterans Administration (VA), and Public Health Service (PHS) programs requires manufacturers to collect, organize, distill and manipulate vast quantities of information, and to generate from that data reportable figures that can have an enormous impact on the company's bottom line. It is critical that these figures be correct, not only to help ensure the integrity of these public programs, but because submission of false data to a federal agency is a prosecutable criminal offense, and the civil penalties and exposure can be staggering.
Apr 01, 2005
Pharmaceutical Executive
Conventional wisdom says that generics businesses are a drain on valuable resources. But these units are much less prone to the disastrous drug safety panics that Big Pharma has recently endured.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Institutions bring value to industry not only through shared coursework or customized training programs, but also through leveraging the intellectual property of institutional personnel for corporate problem solving.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
It is unethical for a retained search firm to fill one client's needs by poaching people from another client that entrusts the firm with its searches and secrets. Partnering—and sharing fees—might be the solution.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Job candidates that evangelize a company are worth more than PR campaigns.
Apr 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
When translating English materials into other languages, be careful of words that mean one thing in one dialect and something else in another dialect. Otherwise, you run the risk of referring to coaches as animal trainers.
Feb 01, 2005
Pharmaceutical Executive
As a reputation driver, ethical behavior has increased steadily in importance over the last three years.
Feb 01, 2005
Pharmaceutical Executive
An effective, high-performing alliance can generate a stronger bottom line outcome.
Jan 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.
Nov 01, 2004
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Sometimes the loss of revenue from a branded drug can outweigh the royalty stream from an authorized generic.
native1_300x100
lorem ipsum